Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 442

1.

Factors associated with surgical morbidity of primary debulking in epithelial ovarian cancer.

Günakan E, Tohma YA, Tunç M, Akıllı H, Şahin H, Ayhan A.

Obstet Gynecol Sci. 2020 Jan;63(1):64-71. doi: 10.5468/ogs.2020.63.1.64. Epub 2019 Dec 31.

2.

Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation Via Protease Activated Receptor-1.

Petzold T, Thienel M, Dannenberg LK, Mourikis P, Helten C, Ayhan A, M'Pembele R, Achilles A, Trojovsky K, Konsek D, Zang Z, Regenauer R, Pircher J, Ehrlich A, Lüsebrink E, Nicolai L, Stocker T, Brandl R, Röschentaler F, Strecker J, Saleh I, Spannagl M, Mayr CH, Schiller HB, Jung C, Gerdes N, Hoffmann T, Levkau B, Hohlfeld T, Zeus T, Schulz C, Kelm M, Polzin A.

Circ Res. 2019 Dec 20. doi: 10.1161/CIRCRESAHA.119.315099. [Epub ahead of print]

PMID:
31859592
3.

Sentinel lymph node biopsy in early stage endometrial cancer: a Turkish gynecologic oncology group study (TRSGO-SLN-001).

Taşkın S, Altin D, Vatansever D, Tokgozoglu N, Karabük E, Turan H, Takmaz Ö, Kahramanoglu I, Naki MM, Güngör M, Köse F, Ortac F, Arvas M, Ayhan A, Taskiran C.

Int J Gynecol Cancer. 2019 Dec 18. pii: ijgc-2019-000847. doi: 10.1136/ijgc-2019-000847. [Epub ahead of print]

PMID:
31857440
4.

The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy.

Aslan K, Meydanli MM, Oz M, Tohma YA, Haberal A, Ayhan A.

J Gynecol Oncol. 2020 Jan;31(1):e1. doi: 10.3802/jgo.2020.31.e1. Epub 2019 Jun 24.

5.

Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease.

Dannenberg L, Metzen D, Zako S, Pöhl M, Mourikis P, Helten C, Trojovsky K, Naguib D, Konsek D, Knoop B, Ayhan A, Hohlfeld T, Petzold T, Levkau B, Veulemans V, Zeus T, Kelm M, Polzin A.

Pharmacology. 2020;105(1-2):118-122. doi: 10.1159/000503582. Epub 2019 Oct 22.

PMID:
31639801
6.

Incidence and outcome of occult uterine sarcoma: A multi-centre study of 18604 operations performed for presumed uterine leiomyoma.

Yorgancı A, Meydanlı MM, Kadıoğlu N, Taşkın S, Kayıkçıoğlu F, Altın D, Atasoy L, Haberal AN, Kınay T, Akgül MA, Tapısız ÖL, Evliyaoğlu Ö, Tekin ÖM, Fırat Ortaç U, Ayhan A.

J Gynecol Obstet Hum Reprod. 2020 Jan;49(1):101631. doi: 10.1016/j.jogoh.2019.101631. Epub 2019 Sep 6. No abstract available.

PMID:
31499285
7.

Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.

Yu Y, Suryo Rahmanto Y, Shen YA, Ardighieri L, Davidson B, Gaillard S, Ayhan A, Shi X, Xuan J, Wang TL, Shih IM.

EBioMedicine. 2019 Sep;47:184-194. doi: 10.1016/j.ebiom.2019.08.055. Epub 2019 Sep 3.

8.

Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for Stage 3C serous ovarian, tubal or peritoneal carcinomas.

Gurkan D, Ceren Akin A, Sahin H, Aytac Tohma Y, Sahin EA, Gunakan E, Iflazoglu N, Nihan Haberal A, Ayhan A.

J Obstet Gynaecol. 2019 Sep 4:1-7. doi: 10.1080/01443615.2019.1634028. [Epub ahead of print]

PMID:
31482736
9.

SATEN III-Splitting Adjuvant Treatment of stage III ENdometrial cancers: an international, multicenter study.

Kahramanoglu I, Meydanli MM, Taranenka S, Ayhan A, Salman C, Sanci M, Demirkiran F, Ortac F, Haidopoulos D, Sukhin V, Kaidarova D, Stepanyan A, Farazaneh F, Aliyev S, Ulrikh E, Kurdiani D, Yalcin İ, Mavrichev S, Akilli H, Sarı ME, Pletnev A, Aslan K, Bese T, Kairbayev M, Vlachos D, Gultekin M.

Int J Gynecol Cancer. 2019 Oct;29(8):1271-1279. doi: 10.1136/ijgc-2019-000643. Epub 2019 Sep 2.

PMID:
31481453
10.

Comparison of survival outcomes in optimally and maximally cytoreduced stage IIIC ovarian high-grade serous carcinoma: Women with only peritoneal tumor burden versus women with both peritoneal and lymphogenous dissemination.

Selcuk I, Meydanli MM, Yalcin I, Gungorduk K, Akgol S, Çelik H, Ayhan A.

J Obstet Gynaecol Res. 2019 Oct;45(10):2074-2081. doi: 10.1111/jog.14075. Epub 2019 Aug 1.

PMID:
31373110
11.

Is the revised 2018 FIGO staging system for cervical cancer more prognostic than the 2009 FIGO staging system for women previously staged as IB disease?

Ayhan A, Aslan K, Bulut AN, Akilli H, Öz M, Haberal A, Meydanli MM.

Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:209-214. doi: 10.1016/j.ejogrb.2019.07.002. Epub 2019 Jul 6.

PMID:
31325847
12.

Para-aortic lymph node involvement revisited in the light of the revised 2018 FIGO staging system for cervical cancer.

Ayhan A, Aslan K, Öz M, Tohma YA, Kuşçu E, Meydanli MM.

Arch Gynecol Obstet. 2019 Sep;300(3):675-682. doi: 10.1007/s00404-019-05232-7. Epub 2019 Jul 1.

PMID:
31263988
13.

Primary lymphomas of the intraabdominal solid organs and the gastrointestinal tract: spectrum of imaging findings with histopathological confirmation.

Karaosmanoglu AD, Uysal A, Onur MR, Hahn PF, Ayhan AS, Ozmen MN, Akata D, Karcaaltincaba M.

Abdom Radiol (NY). 2019 Sep;44(9):2988-3005. doi: 10.1007/s00261-019-02100-5. Review.

PMID:
31209544
14.

Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.

Park Y, Chui MH, Suryo Rahmanto Y, Yu ZC, Shamanna RA, Bellani MA, Gaillard S, Ayhan A, Viswanathan A, Seidman MM, Franco S, Leung AKL, Bohr VA, Shih IM, Wang TL.

Clin Cancer Res. 2019 Sep 15;25(18):5584-5594. doi: 10.1158/1078-0432.CCR-18-4222. Epub 2019 Jun 13.

PMID:
31196855
15.

Uterine smooth muscle tumor of uncertain malignant potential: fertility and clinical outcomes.

Şahin H, Karatas F, Coban G, Özen Ö, Erdem Ö, Onan MA, Ayhan A.

J Gynecol Oncol. 2019 Jul;30(4):e54. doi: 10.3802/jgo.2019.30.e54. Epub 2019 Feb 4.

16.
17.

A novel prediction method for lymph node involvement in endometrial cancer: machine learning.

Günakan E, Atan S, Haberal AN, Küçükyıldız İA, Gökçe E, Ayhan A.

Int J Gynecol Cancer. 2019 Feb;29(2):320-324. doi: 10.1136/ijgc-2018-000033. Epub 2018 Dec 28.

PMID:
30718313
18.

Prognostic significance of lymphovascular space invasion in low-risk endometrial cancer.

Ayhan A, Şahin H, Sari ME, Yalçin I, Haberal A, Meydanli MM.

Int J Gynecol Cancer. 2019 Mar;29(3):505-512. doi: 10.1136/ijgc-2018-000069. Epub 2019 Jan 21.

PMID:
30665899
19.

Recurrence patterns and prognostic factors in lymphovascular space invasion-positive endometrioid endometrial cancer surgically confined to the uterus.

Sahin H, Meydanli MM, Sari ME, Kocaman E, Cuylan ZF, Yalcin I, Coban G, Özen Ö, Sirvan L, Güngör T, Ayhan A.

Taiwan J Obstet Gynecol. 2019 Jan;58(1):82-89. doi: 10.1016/j.tjog.2018.11.016.

20.

Risk Factors for Lymph Node Metastasis among Lymphovascular Space Invasion-Positive Women with Endometrioid Endometrial Cancer Clinically Confined to the Uterus.

Sarı ME, Meydanlı MM, Yalçın I, Şahin H, Çoban G, Çelik H, Kuşçu E, Gungor T, Ayhan A.

Oncol Res Treat. 2018;41(12):750-754. doi: 10.1159/000492585. Epub 2018 Nov 13.

21.

Comparison of stage III mucinous and serous ovarian cancer: a case-control study.

Firat Cuylan Z, Karabuk E, Oz M, Turan AT, Meydanli MM, Taskin S, Sari ME, Sahin H, Ulukent SC, Akbayir O, Gungorduk K, Gungor T, Kose MF, Ayhan A.

J Ovarian Res. 2018 Oct 30;11(1):91. doi: 10.1186/s13048-018-0464-2.

22.

Oncological and obstetric outcomes after fertility-sparing radical abdominal trachelectomy for early stage cervical cancer: a tertiary centre's 10 years' experience.

Ayhan A, Tohma YA, Sahin H, Kocaman E, Tunc M, Haberal AN.

J Obstet Gynaecol. 2019 Feb;39(2):248-252. doi: 10.1080/01443615.2018.1498830. Epub 2018 Oct 27.

PMID:
30371139
23.

The prognostic significance of stage I ovarian clear cell and endometrioid carcinomas arising from endometriotic cysts: is it a myth?

Ayhan A, Akilli H, Haberal N.

Arch Gynecol Obstet. 2019 Jan;299(1):217-222. doi: 10.1007/s00404-018-4935-x. Epub 2018 Oct 12.

PMID:
30315413
24.

Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).

Antmen B, Karakaş Z, Yeşilipek MA, Küpesiz OA, Şaşmaz İ, Uygun V, Kurtoğlu E, Oktay G, Aydogan G, Akın M, Salcioglu Z, Vergin C, Kazancı EG, Ünal S, Çalışkan Ü, Aral YZ, Türkkan E, Meral Güneş A, Tunç B, Gümrük F, Ayhan AC, Söker M, Koç A, Oymak Y, Ertem M, Timur Ç, Yıldırmak Y, İrken G, Apak H, Biner B, Eren TG, Işık Balcı Y, Koçak Ü, Karasu G, Akkaynak D, Patıroğlu T.

Eur J Haematol. 2019 Feb;102(2):123-130. doi: 10.1111/ejh.13180. Epub 2018 Dec 9.

PMID:
30300449
25.

Bilateral synchronous ovarian tumours: an uncommon case and review of the literature.

Günakan E, Tohma YA, Haberal AN, Ayhan A.

Prz Menopauzalny. 2018 Jun;17(2):97-100. doi: 10.5114/pm.2018.77312. Epub 2018 Jun 30.

26.

Retrospective Evaluation of Patients who Underwent Laparoscopic Bariatric Surgery.

Tuncalı B, Pekcan YÖ, Ayhan A, Erol V, Yılmaz TH, Kayhan Z.

Turk J Anaesthesiol Reanim. 2018 Aug;46(4):297-304. doi: 10.5152/TJAR.2018.72687. Epub 2018 Aug 1.

27.

Prevalence of endometrial cancer or atypical hyperplasia diagnosed incidentally in infertility clinic.

Tohma YA, Zeyneloglu HB, Aslan OD, Haberal AN, Onalan G, Ayhan A.

Am J Obstet Gynecol. 2018 Nov;219(5):503-505. doi: 10.1016/j.ajog.2018.08.008. Epub 2018 Aug 15. No abstract available.

PMID:
30118694
28.

Risk Factors for Recurrence in Low-Risk Endometrial Cancer: A Case-Control Study.

Güngördük K, Firat Cüylan Z, Kahramanoglu I, Oge T, Akbayir O, Dede M, Taşkın S, Ozgul N, Simsek T, Turan H, Gülseren V, Ozdemir A, Meydanlı MM, Ayhan A.

Oncol Res Treat. 2018;41(7-8):466-470. doi: 10.1159/000488112. Epub 2018 Jul 6.

29.

Possible impact of immunosuppressive therapy regimens on histopathologic outcomes of abnormal uterine bleeding in solid-organ transplant recipients.

Tohma YA, Akilli H, Kirnap M, Haberal AN, Akyel D, Zengin HY, Zeyneloglu HB, Kuscu E, Ayhan A, Haberal M.

Clin Transplant. 2018 Aug;32(8):e13305. doi: 10.1111/ctr.13305. Epub 2018 Jun 15.

PMID:
29851156
30.

Impact of lymph node ratio on survival in stage IIIC endometrioid endometrial cancer: a Turkish Gynecologic Oncology Group study.

Ayhan A, Topfedaisi Ozkan N, Öz M, Kimyon Comert G, Firat Cuylan Z, Çoban G, Turkmen O, Erdem B, Şahin H, Akbayır Ö, Dede M, Turan AT, Celik H, Güngör T, Haberal A, Arvas M, Meydanli MM.

J Gynecol Oncol. 2018 Jul;29(4):e48. doi: 10.3802/jgo.2018.29.e48. Epub 2018 Mar 13.

31.

Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.

Cuylan ZF, Meydanli MM, Sari ME, Akbayir O, Celik H, Dede M, Sahin H, Gungorduk K, Kuscu E, Ozgul N, Gungor T, Ayhan A.

J Obstet Gynaecol Res. 2018 Jul;44(7):1284-1293. doi: 10.1111/jog.13663. Epub 2018 May 4.

PMID:
29727055
32.

Independent development of endometrial epithelium and stroma within the same endometriosis.

Noë M, Ayhan A, Wang TL, Shih IM.

J Pathol. 2018 Jul;245(3):265-269. doi: 10.1002/path.5082. Epub 2018 May 2.

PMID:
29604057
33.

Prognostic factors and patterns of recurrence in lymphovascular space invasion positive women with stage IIIC endometriod endometrial cancer.

Cuylan ZF, Oz M, Ozkan NT, Comert GK, Sahin H, Turan T, Akbayir O, Kuscu E, Celik H, Dede M, Gungor T, Meydanli MM, Ayhan A.

J Obstet Gynaecol Res. 2018 Jun;44(6):1140-1149. doi: 10.1111/jog.13615. Epub 2018 Mar 8.

PMID:
29516573
34.

Platelet function testing: dead or alive.

Helten C, Naguib D, Dannenberg L, Pöhl M, Ayhan A, Hohlfeld T, Levkau B, Kelm M, Zeus T, Polzin A.

J Thromb Haemost. 2018 May;16(5):984-986. doi: 10.1111/jth.13997. Epub 2018 Apr 2.

PMID:
29512292
35.

Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?

Sahin H, Meydanli MM, Sari ME, Yalcin I, Çoban G, Ozkan NT, Cuylan ZF, Erdem B, Gungorduk K, Akbayir Ö, Dede M, Salman MC, Güngör T, Ayhan A.

J Ovarian Res. 2018 Mar 5;11(1):21. doi: 10.1186/s13048-018-0393-0.

36.

Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?

Sahin H, Sari ME, Cuylan ZF, Haberal AN, Sirvan L, Coban G, Yalcin I, Güngör T, Celik H, Meydanli MM, Ayhan A.

Arch Gynecol Obstet. 2018 Apr;297(4):1005-1013. doi: 10.1007/s00404-018-4651-6. Epub 2018 Jan 30.

PMID:
29383437
37.

Impact of lymph node ratio on survival in stage III ovarian high-grade serous cancer: a Turkish Gynecologic Oncology Group study.

Ayhan A, Ozkan NT, Sarı ME, Celik H, Dede M, Akbayır Ö, Güngördük K, Şahin H, Haberal A, Güngör T, Arvas M, Meydanlı MM.

J Gynecol Oncol. 2018 Jan;29(1):e12. doi: 10.3802/jgo.2018.29.e12.

38.

Diagnostic immunohistochemistry in gynaecological neoplasia: a brief survey of the most common scenarios.

Kuhn E, Ayhan A.

J Clin Pathol. 2018 Feb;71(2):98-109. doi: 10.1136/jclinpath-2017-204787. Epub 2017 Nov 28. Review.

PMID:
29183921
39.

Elucidating the pathogenesis of synchronous and metachronous tumors in a woman with endometrioid carcinomas using a whole-exome sequencing approach.

Wu RC, Veras E, Lin J, Gerry E, Bahadirli-Talbott A, Baras A, Ayhan A, Shih IM, Wang TL.

Cold Spring Harb Mol Case Stud. 2017 Nov 21;3(6). pii: a001693. doi: 10.1101/mcs.a001693. Print 2017 Nov.

40.

Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.

Yalcin I, Meydanli MM, Turan AT, Taskin S, Sari ME, Gungor T, Akbayir O, Ayhan A.

Int J Clin Oncol. 2018 Apr;23(2):329-337. doi: 10.1007/s10147-017-1215-x. Epub 2017 Nov 16.

PMID:
29143144
41.

High grade serous ovarian carcinomas originate in the fallopian tube.

Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE.

Nat Commun. 2017 Oct 23;8(1):1093. doi: 10.1038/s41467-017-00962-1.

42.

Comparison of three different risk-stratification models for predicting lymph node involvement in endometrioid endometrial cancer clinically confined to the uterus.

Korkmaz V, Meydanli MM, Yalçın I, Sarı ME, Sahin H, Kocaman E, Haberal A, Dursun P, Güngör T, Ayhan A.

J Gynecol Oncol. 2017 Nov;28(6):e78. doi: 10.3802/jgo.2017.28.e78.

43.

The preoperative albumin level is an independent prognostic factor for optimally debulked epithelial ovarian cancer.

Ayhan A, Günakan E, Alyazıcı İ, Haberal N, Altundağ Ö, Dursun P.

Arch Gynecol Obstet. 2017 Nov;296(5):989-995. doi: 10.1007/s00404-017-4511-9. Epub 2017 Sep 5.

PMID:
28875365
44.

Factors associated with survival after relapse in patients with low-risk endometrial cancer treated with surgery alone.

Topfedaisi Ozkan N, Meydanlı MM, Sarı ME, Demirkiran F, Kahramanoglu I, Bese T, Arvas M, Şahin H, Haberal A, Celik H, Coban G, Oge T, Yalcin OT, Akbayır Ö, Erdem B, Numanoğlu C, Özgül N, Boyraz G, Salman MC, Yüce K, Dede M, Yenen MC, Taşkın S, Altın D, Ortaç UF, Aydın Ayık H, Şimşek T, Güngör T, Güngördük K, Sancı M, Ayhan A.

J Gynecol Oncol. 2017 Sep;28(5):e65. doi: 10.3802/jgo.2017.28.e65. Epub 2017 Jun 16.

45.

Prognostic factors and treatment outcomes in surgically-staged non-invasive uterine clear cell carcinoma: a Turkish Gynecologic Oncology Group study.

Sarı ME, Meydanlı MM, Türkmen O, Cömert GK, Turan AT, Karalök A, Şahin H, Haberal A, Kocaman E, Akbayır Ö, Erdem B, Numanoğlu C, Güngördük K, Sancı M, Gökçü M, Özgül N, Salman MC, Boyraz G, Yüce K, Güngör T, Taşkın S, Altın D, Ortaç UF, Ayık HA, Şimşek T, Arvas M, Ayhan A.

J Gynecol Oncol. 2017 Jul;28(4):e49. doi: 10.3802/jgo.2017.28.e49.

46.

Cancer-Associated Mutations in Endometriosis without Cancer.

Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V, Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W, Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong PJ, Huntsman DG, Shih IM.

N Engl J Med. 2017 May 11;376(19):1835-1848. doi: 10.1056/NEJMoa1614814.

47.

Gynecologic Oncologist Perspective About ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer.

Dursun P, Ayhan A.

Int J Gynecol Cancer. 2017 May;27(4):826-831. doi: 10.1097/IGC.0000000000000931.

PMID:
28441254
48.

Incidence and Patient Outcomes in Renal Replacement Therapy After Orthotopic Liver Transplant.

Ayhan A, Ersoy Z, Ulas A, Zeyneloglu P, Pirat A, Haberal M.

Exp Clin Transplant. 2017 Feb;15(Suppl 1):258-260.

49.

Anesthetic and Perioperative Management of Nontransplant Surgery in Patients After Liver Transplant.

Ersoy Z, Ayhan A, Ozdemirkan A, Polat GG, Zeyneloglu P, Arslan G, Haberal M.

Exp Clin Transplant. 2017 Feb;15(Suppl 1):42-45.

50.

Potential role of increasing number of sections in frozen section diagnosis of ovarian tumors.

Ayhan A, Ozler A, Dursun P, Haberal AN.

J Exp Ther Oncol. 2016 Nov;11(4):245-250.

PMID:
27849334

Supplemental Content

Support Center